TGTX

TG Therapeutics, Inc. Press Releases

$16.45
*  
0.75
4.78%
Get TGTX Alerts
*Delayed - data as of Dec. 19, 2014  -  Find a broker to begin trading TGTX now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
TG Therapeutics, Inc. Announces Appointment of Kenneth Hoberman to Board of Directors
12/17/2014 8:30:00 AM - GlobeNewswire


Preliminary Data From Ongoing Phase I/II Dose Escalation Study of TG-1101 (Ublituximab) in Combination With TGR-1202 in Heavily Pre-treated Relapsed/Refractory B-Cell Malignancies Demonstrates Encouraging Clinical Activity and Safety
12/9/2014 11:10:00 AM - GlobeNewswire


Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical Activity in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL)
12/8/2014 1:41:00 PM - GlobeNewswire


Interim Data From Phase 1 Dose Escalation Clinical Trial of TGR-1202, the Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity and Lack of Hepatic Toxicity in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Ho
12/6/2014 6:55:00 PM - GlobeNewswire


TG Therapeutics Announces Collaboration for a Clinical Trial of TGR-1202 in Combination With Ibrutinib (Imbruvica(R)) for Patients With Select B-Cell Malignancies
12/1/2014 8:30:00 AM - GlobeNewswire


Highpower International to Present at the 7th Annual LD Micro Main Event on December 2, 2014
12/1/2014 8:30:00 AM - PR Newswire


TG Therapeutics, Inc. to Present at the 2014 Deutsche Bank BioFEST Conference
11/25/2014 4:30:00 PM - GlobeNewswire


TG Therapeutics, Inc. Announces Third Quarter 2014 Financial Results and Business Update
11/10/2014 4:15:00 PM - GlobeNewswire


TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2014 Financial Results and Business Update
11/7/2014 4:00:00 PM - GlobeNewswire


TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 56th American Society of Hematology Annual Meeting
11/6/2014 9:30:00 AM - GlobeNewswire


TG Therapeutics Announces Exercise of License Option for Its Novel, Next Generation PI3K-Delta Inhibitor, TGR-1202
9/23/2014 7:30:00 AM - GlobeNewswire